Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 11/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.37 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4161480 | 0.89 | HDAC4 (0.43) | GSK3BALDH1A1PARP1 | |
| SCHEMBL4162767 | 0.87 | GSK3B (0.41) | GSK3BALDH1A1HPGDCYP1A2CYP2C19 | |
| SCHEMBL4152071 | 0.85 | RAD52 (0.41) | GSK3BALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4145524 | 0.84 | GSK3B (0.45) | GSK3BCYP1A2CYP2C19PARP1MAPK14 | |
| SCHEMBL8234676 | 0.83 | NPC1 (0.34) | GSK3BALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13778306 | 0.78 | GSK3B (0.40) | GSK3BCYP1A2CYP2C19PARP1MAPK14 | |
| SCHEMBL4165073 | 0.78 | GSK3B (0.45) | GSK3BPARP1 | |
| SCHEMBL4157107 | 0.77 | DHODH (0.49) | GSK3BPARP1MAPK14 | |
| SCHEMBL4152713 | 0.77 | SYK (0.43) | GSK3BPARP1 | |
| SCHEMBL4165287 | 0.77 | GSK3B (0.44) | GSK3BPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170847-A1 | Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same | YUYU PHARMA, INC. (KR) | 2009-07-02 | — | — | US | disclosed |
| US-20090170847-A1 | Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same | YUYU PHARMA, INC. (KR) | 2009-07-02 | — | — | US | disclosed |
| US-20090170847-A1 | Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same | YUYU PHARMA, INC. (KR) | 2009-07-02 | — | — | US | disclosed |
| WO-2007083978-A1 | IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | CRYSTALGENOMICS, INC. (KR) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170847-A1 | Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same | GSK3B, GSK3A, MAP3K3 | GSK3B 1/4885ALDH1A1 4274/4885NPC1 2497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.